Furthermore, the inability to measure GSH levels in the CNS has markedly impaired the development of new trials focused on increasing GSH levels
Novo Nordisk filed a patent infringement lawsuit
Without lifestyle changes, weight regain is common after discontinuing GLP-1 receptor agonists
On the other hand, Mounjaro delivers even greater metabolic benefits, with studies showing up to 20% weight loss, making it a formidable contender for both diabetes and obesity treatment
Launching a GLP-1 virtual clinic platform is deceptively complex
Assessment of drug effects in mice with genetic or pharmacological inhibition of GLP-1R, GIPR or PPAR showed that GLP-1GIPLani decreases body weight via both incretin receptors, while further improving glucose metabolism via PPAR (Fig